Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International PublicationsEx vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant MelanomaOncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusEmerging Immunotherapies in the Treatment of Brain Metastases
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusSynergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusBlockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsEmerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Pleural MesotheliomaTriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant MelanomaBlockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de